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Abstract Monoclonal antibodies (MAbs) usually display
slow and limited distribution with combined linear and
non-linear elimination mechanisms. While studying indi-
vidual pharmacokinetic profiles, it was noticed that MAb
plasma concentration can vary abruptly over time, with one
or more increases after the time to maximum plasma
concentration when theoretically the concentration should
only decline. This article summarizes the frequency of
these additional peaks and assesses whether normal intra-
subject and assay variability can explain the observations.
For this analysis, we used a benchmark consisting of three
registered (adalimumab, bevacizumab, and trastuzumab)
and three unregistered immunoglobulin G1 MAbs. At a
selected ‘normal’ intra-subject variability of 12%, at least
70% of the study participants (approximately 90% for
certain MAbs) still had at least one additional peak, which
decreased when the ‘normal’ variability was increased.
There was no difference in occurrence between the high-
and low-concentration ranges. Only a high sample density
was associated with an increased likelihood of detecting
additional peaks. Based on the analytical variability for the
applied ligand-binding assays (5–10%, up to 15% at the
lower limit of quantitation), the number of observed
increases was extremely improbable (p\ 0.01) for most
MAbs, especially for the large excursions. Therefore, the
fluctuations are likely genuine. We discuss the possible
explanations and the relevance for clinical practice.
Key Points
The plasma concentration–time course of
monoclonal antibodies can show considerable
fluctuations in individuals that cannot be explained
by physiological or assay variability.
More research is required to elucidate which in vivo
mechanism(s) are responsible for the observed
fluctuations and to determine its relevance for
clinical practice.
1 Introduction
Monoclonal antibodies (MAbs) are widely used to treat
diseases in almost all fields of medicine. They display
highly similar pharmacokinetics with a relatively small
volume of distribution and a long half-life. Many of the
mechanisms responsible for these properties have been
extensively studied and are excellently reviewed elsewhere
[1–5].
At the Centre for Human Drug Disease, multiple clinical
trials with MAbs are performed annually. When studying
their pharmacokinetics, it was noticed that plasma con-
centrations of MAbs in individuals can follow a remark-
able, or even bizarre, time course, characterized by (large)
excursions (Fig. 1), which seems to be in disagreement
with the current understanding of drug distribution and/or
elimination.
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Initially, these findings were disregarded as normal
intra-subject and assay variability, also because the mean
(group) pharmacokinetic profile usually follows a pre-
dictable time course of slow distribution combined with
both linear and non-linear elimination. However, after
observing fluctuating individual plasma concentrations for
an increasing number of MAbs, it was considered worth-
while to analyze individual profiles systematically, with the
objective to determine if the fluctuations are genuine. A
benchmark was used to assess if the result could indeed be
explained by normal intra-subject and assay variability, or
that other factors may be involved.
2 Methods
Pharmacokinetic data were taken from clinical trials with
MAbs in healthy volunteers. Three registered MAbs
(adalimumab [Humira, AbbVie Ltd, Maidenhead, United
Kingdom], bevacizumab [Avastin, Roche Pharma AG,
Grenzach-Wyhlen, Germany], trastuzumab [Herceptin,
Roche Pharma AG, Grenzach-Wyhlen, Germany]) were
analyzed, as well as three unregistered products (denoted
A, B, and C). All drugs were immunoglobulin G1 anti-
bodies and were administered as a single intravenous dose,
except for adalimumab, which was administered subcuta-
neously. The trial participants were healthy subjects,
mainly male individuals aged 18–50 years, but some trials
included up to 50% female individuals.
All trial procedures were performed in accordancewith the
different trial protocols. Samples were collected and handled
following standard operating procedures.Within each clinical
trial, MAb plasma concentration was determined in a single
external laboratory and in a single analytical run per partici-
pant using validated methods. Product C was quantitated in
batches of samples across multiple subjects, resulting in more
than one analytical run per participant.
To determine if intra-subject variability for MAb plasma
concentration would be related to, for example, changes in
circulating plasma volume, the time course of albumin
plasma concentration and erythrocyte counts were studied.
As albumin and erythrocytes are produced at a relatively
constant rate and under normal circumstances do not leave
the intravascular compartment, these analytes were con-
sidered suitable benchmarks.
Samples for albumin concentration and erythrocyte count
were always collected concurrently with samples for MAb
concentration, albeit at a lesser frequency. On the adminis-
tration day, albumin and erythrocytes were quantitated one
to five times, depending on the trial protocol. Thereafter, the
ratio of the number of these samples to the number of
pharmacokinetic samples ranged between 0.5 and 1. The
mean of the individual coefficients of variation (CVs) of
albumin concentration per clinical trial (70\ n\200)
varied between 3.6 and 4.4% with standard deviations of
1.2–1.2%-point. For the erythrocyte count, the mean ranged
between 2.7 and 3.7% and the standard deviations between
0.75 and 1.2%-point, irrespective if only samples collected
on the same day (hours apart) or during the full length of the
trial (days to weeks apart) were included in the calculation.
Hence, it appears that a conservative reference CV
(CVref) of 4% for normal intra-subject variability (CVi) is
justified. It was subsequently investigated whether the
observed fluctuations in MAb plasma concentration
exceeded 1, 2, or 3 CVsref, indicating an increasing
unlikeliness a change in the profile can be explained by
‘normal (physiological) variability’. Additionally, we
considered a less conservative CVref of 8%, covering
approximately two CVs of the observed variability for
albumin and erythrocytes, and a very extreme variability of
50%. By applying this strategy to pharmacokinetic data for
different MAbs, the number of relative maxima in the
concentration–time profile (other than the absolute maxi-
mum plasma concentration) that cannot be ascribed to the
chosen intra-subject variability was counted.
Excursions beyond normal intra-subject variability were
identified based on a deviation in the exponential growth
constant (k) outside the margins determined by 1–3 CVref
(4, 8, and 12%) of the conservative variability estimate or
of the less conservative CVref (8, 16, and 24%). The mar-
gins for k per observation were derived from the formula
A ± CVi = Bekt, where A is the observed plasma con-
centration, CVi is the chosen intra-subject variability, B is
the plasma concentration of the previous sample, and t is
the difference in sample collection time between A and
B. Next, the minimum number of unique ks was deter-
mined to describe the observations (A ± CVi) per indi-
vidual. A deviation in k beyond the chosen intra-subject
variability was defined as the requirement of two or more
unique ks to describe the rising leg of the plasma con-
centration curve before a relative (local) maximum was
reached (see Supplementary Figure for an example).
This approach assumes linear elimination kinetics,
which is known not to be the case for MAbs. However, the
plasma concentration–time profile of MAbs usually
approximates linearity at the observed (high) MAb plasma
concentrations in healthy volunteers where the non-linear
elimination mechanism is saturated. Additionally, the non-
linearity in elimination manifests as different negative ks,
whereas the focus of this analysis was on deviations from
the surrounding data points in the k in the rising parts of the
plasma concentration–time profile. Therefore, this
approach was considered fit for purpose.
A separation was made between peaks occurring within
the first 24 h from intravenous administration, or 14 days
from subcutaneous administration, and thereafter.





Fig. 1 Individual pharmacokinetic profiles. Representative patterns
in individual plasma drug concentrations over time for registered
monoclonal antibodies: 2 mg/kg intravenous bevacizumab (a–d),
6 mg/kg intravenous trastuzumab (e–g), and 40 mg subcutaneous
adalimumab (h–j). The insets depict an enlarged section of the first
part of the profile. The dashed lines mark the end of intravenous
administration
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Additionally, the results of the intravenously administered
compounds were stratified based on dose.
To study the potential impact of assay variability, the
total number of increases between relative extremes Ck in
the individual plasma concentration–time profiles was
compared with the expected number based on the CV of
the used bioanalytical assays (CVassay). Here, k is a factor
for which values were chosen as 1.12, 1.25, 1.5, 2, 3, 4, and
5, corresponding to increases between 12 and 400%. A
one-tailed binomial test was performed to determine the
probability (p) of finding at least the observed number of
increases Ck. Samples collected before or during infusion
were excluded. This analysis could only be performed for
intravenously administered MAbs.
The expected number of increases Ck between two
consecutive extremes was calculated using the method by
Reed and co-workers [6]. This approach assumes that the
plasma concentration between two samples remains con-
stant, which results in an underestimation of the observed
number of increases Ck, as the plasma concentration the-
oretically declines after the completion of intravenous
administration. Because the p values of increases Ck at any
CVassay derived with the binomial tests are thereby over-
estimated, thus favoring the probability of increases being
attributed to assay variability, this methodological short-
coming was accepted.
According to the regulatory guidelines for ligand-bind-
ing assays (the type usually applied when measuring MAbs
in plasma), the CVassay should not exceed 20%, except at
the lower level of quantitation, where it should not exceed
25% [7, 8]. The actual CVassay for the bio-analyses applied
in the clinical studies ranged between 5 and 10%, with
higher levels (up to 15%) found at the lower level of
quantitation. Therefore, p values were obtained at different
CVassays from 5 to 25%.
Data analysis was performed with R (Version 2.15.2; R
Foundation for Statistical Computing, Vienna, Austria [R
Development Core Team 2012]).
3 Results
Pharmacokinetic observations were available for 130 sub-
jects receiving adalimumab (mean 26.1 observations per
subject), 90 subjects receiving bevacizumab (mean 26.3),
and 46 subjects receiving trastuzumab (mean 19.8). For
products A, B, and C, data were available from respec-
tively 18, 33, and 7 subjects, with a mean number of
observations of 18.9, 15.1, and 17.4, respectively. The
samples collected during the first 7 days after administra-
tion summed 16 for adalimumab, 15 for bevacizumab, 12
for trastuzumab, 12 for A, 10 for B, and 10 for C.
Tables 1 and 2 present the number of subjects with
additional maxima beyond increasing CVi. This shows that
with a conservative CVi of 4% virtually all subjects had an
additional peak in their profile. Even if the variability con-
sidered normal is increased to 3 CVref (12%), at least 70% of
the study participants (approximately 90% for certainMAbs)
still had at least one additional peak, with the exception of
products B and C. It should be noted, however, that for both
products B and C a sparse sampling scheme was used com-
pared with the other MAbs, with fewer than five samples
collected during the first 24 h. This may have limited the
chance to identify short-lasting concentration changes.
At a variability of 24%, 60–70% of subjects who received
bevacizumab, trastuzumab, or product A showed an unex-
plained additional relative maximum, a percentage that
decreased further and became more dispersed among the
MAbs at a variability of 50%. For adalimumab, product B and
C, the corresponding numbers were again lower, although the
overall pattern observed with increasing intra-subject vari-
ability was similar for all investigated MAbs. Even when
considering an intra-subject variability of 24 or 50% as nor-
mal, which is well beyond the variability (CVref) observed for
albumin and erythrocytes, additional peaks remain.
The probability of finding a number of increases with a
certain magnitude in plasma concentration rose with
increasing assay variability (Table 3). Conversely, the
i j
Fig. 1 continued
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probability was lower for larger excursions. Within the
actual CV range for the used ligand-binding assays (5–10%),
the number of observed increases was extremely improbable
based on assay variability, except for product C. Even at
higher CVassays, which are only accepted at the lower level of
quantitation (up to 15% for the used assays), assay variability
must be considered unlikely in causing the observed
increases, especially for those with a large amplitude.
A relationship between standard demographic param-
eters (age, [lean] body weight, body mass index) and the
number or magnitude of additional peaks could not be
detected, although it should be noted that, as a result of
the trial protocols, the populations were highly homoge-
neous with regard to these parameters. Additionally,
across the different trials, demographic variability was
limited.
Table 1 Additional peak
concentrations after intravenous
administration
MAb/period (h) Variability, n (%)
4% 8% 12% 16% 24% 50%
Dose B3 mg/kg
Bevacizumab (n = 90)
Total 88 (97.8) 87 (96.7) 83 (92.2) 72 (80.0) 65 (72.2) 41 (45.6)
\24 82 (91.1) 79 (87.8) 68 (75.6) 54 (60.0) 46 (51.1) 25 (27.8)
C24 73 (81.1) 70 (77.8) 66 (73.3) 61 (67.8) 56 (62.2) 30 (33.3)
A (n = 18)
Total 18 (100) 17 (94.4) 16 (88.9) 16 (88.9) 12 (66.7) 1 (5.6)
\24 18 (100) 17 (94.4) 16 (88.9) 16 (88.9) 12 (66.7) 1 (5.6)
C24 4 (22.2) 4 (22.2) 4 (22.2) 4 (22.2) 4 (22.2) 0
B (n = 33)
Total 12 (36.4) 12 (36.4) 7 (21.2) 5 (15.2) 3 (9.1) 1 (3.0)
\24 8 (24.2) 8 (24.2) 4 (12.1) 2 (6.1) 1 (3.0) 0
C24 4 (12.1) 4 (12.1) 3 (9.1) 3 (9.1) 2 (6.1) 1 (3.0)
Dose[3 mg/kg
Trastuzumab (n = 46)
Total 46 (100) 44 (95.7) 42 (91.3) 37 (80.4) 28 (60.9) 8 (17.4)
\24 45 (97.8) 42 (91.3) 39 (84.8) 33 (71.7) 22 (47.8) 3 (6.5)
C24 21 (45.7) 21 (45.7) 20 (43.5) 20 (43.5) 16 (34.8) 5 (10.9)
C (n = 7)
Total 3 (42.9) 3 (42.9) 2 (28.6) 1 (14.3) 0 0
\24 2 (28.6) 2 (28.6) 2 (28.6) 1 (14.3) 0 0
C24 1 (14.3) 1 (14.3) 0 0 0 0
Number (%) of subjects with at least one peak concentration other than the maximum plasma concentration
beyond ‘normal’ intra-subject variability, for which values between 4 and 50% were chosen. Values are
displayed per MAb. A separation is made between peaks occurring within the first 24 h from administration
and thereafter. A, B, and C are unregistered IgG1 antibodies
MAb monoclonal antibody, IgG1 immunoglobulin G1
Table 2 Additional peak
concentrations after
subcutaneous administration
Period (days) Variability, n (%)
4% 8% 12% 16% 24% 50%
Total 128 (98.5) 118 (90.8) 90 (69.2) 72 (55.4) 54 (41.5) 19 (14.6)
\14 127 (97.7) 116 (89.2) 87 (66.9) 70 (53.8) 48 (36.9) 15 (11.5)
C14 13 (10.0) 13 (10.0) 12 (9.2) 11 (8.5) 11 (8.5) 8 (6.2)
Number (%) of subjects with at least one peak concentration other than the maximum plasma concentration
beyond ‘normal’ intra-subject variability after a single subcutaneous dose of 40 mg adalimumab (n = 130).
Values for normal intra-subject variability were chosen between 4 and 50%. A separation is made between
peaks occurring within the first 14 days from administration and thereafter
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Table 3 Probability of
increases based on assay
variability
MAb/factor (k) Observed CVassay
5% 10% 15% 20% 25%
Dose B3 mg/kg
Bevacizumab
1.12 228 \10-93 \10-5 0.86 1.00 1.00
1.25 153 \10-99 \10-37 \10-3 0.97 1.00
1.5 78 \10-99 \10-99 \10-20 0.01 0.99
2 23 \10-99 \10-99 \10-31 \10-7 0.20
3 8 \10-99 \10-97 \10-37 \10-16 \10-6
4 3 \10-99 \10-59 \10-23 \10-11 \10-5
5 2 \10-99 \10-53 \10-22 \10-11 \10-5
A
1.12 34 \10-18 \10-3 0.10 0.39 0.62
1.25 19 \10-39 \10-5 0.08 0.64 0.92
1.5 10 \10-70 \10-14 \10-3 0.16 0.73





1.12 3 0.76 1.00 1.00 1.00 1.00
1.25 1 0.06 0.99 1.00 1.00 1.00
1.5 1 \10-6 0.14 0.86 1.00 1.00
2 1 \10-20 \10-4 0.04 0.38 0.82





1.12 75 \10-29 0.02 0.90 1.00 1.00
1.25 26 \10-43 0.01 1.00 1.00 1.00
1.5 5 \10-31 \10-3 0.89 1.00 1.00
2 1 \10-19 \10-3 0.14 0.85 1.00
3 1 \10-51 \10-12 \10-4 0.01 0.21
4 1 \10-82 \10-19 \10-8 \10-3 \10-2
5 0
C







Probability (p) of finding the observed number of increases Ck in plasma concentration based on the
CVassay. Only increases after completion of intravenous administration are considered
CVassay assay’s coefficient of variation, MAb monoclonal antibody
J. A. A. Reijers et al.
4 Discussion
In this article, it is reported that MAbs may show unex-
pected and remarkable pharmacokinetic behavior with
increases in plasma concentrations at the time the com-
pound is cleared. These increases, which are occasionally
substantial and long lasting, cannot be explained by
physiological or assay variability. There was no difference
in occurrence between the high- and low-concentration
ranges. Only a high sample density seemed to be associated
with an increased likelihood of detecting additional peaks.
When observing fluctuations, especially increases, in the
concentration of a drug over time that theoretically should
decline steadily, there are a few explanations to consider.
First, pre-analytical errors such as not disconnecting and
removal of the infusion material upon stopping intravenous
administration, sample switching, applying incorrect dilu-
tions, or calculation errors, should be ruled out. Subse-
quently, the assay performance should be considered
critically, including, among others, assay precision, within
and between-run variability, limit of quantitation, and
effects of freeze-thaw cycles.
For multiple reasons, assay variability or interference
was considered unlikely to explain our observations. First,
a vast number of additional peaks were counted (Table 3).
Additionally, the finding that comparable fluctuations were
observed for all investigated MAbs, in each assay, both in
the low- and high-concentration ranges, and at any moment
in time after administration (Fig. 1) argues against an
assay-related explanation. Furthermore, the data points
before or after the peak often confirmed the relatively high
concentration or suggested a steady increase towards the
maximum, respectively, a decrease following the maxi-
mum. These observations are generally not compatible
with the randomness one expects to arise from assay
variability.
Another explanation to consider is physiological vari-
ability, as for instance, changes in volume status over time
may alter the concentration of the MAb in plasma, while
the absolute quantity in the body remains unchanged. Fluid
shifts were recently postulated by Van Iersel et al. [9] as
the underlying mechanism for the postural changes in MAb
concentrations that they had observed. Similar day-to-day
variability was seen in our study with adalimumab. In that
clinical trial, pharmacokinetic samples were collected 12 h
apart during the first week (Fig. 1h–j). The evening con-
centrations (0.5, 1.5, 2.5, … days after administration)
were higher than the morning concentrations (1, 2, 3, …
days after administration), with a mean difference of 13.3%
(standard deviation 10.5%-point) per participant. It should
be noted, however, that for the main part of the adali-
mumab trial the participants were ambulatory and traveled
both in the morning and evening to the clinical unit,
making postural changes unlikely.
Additionally, the magnitude of many of the remaining
fluctuations in plasma concentration for the investigated
MAbs (Fig. 1) exceeded by far the reported increases by
Van Iersel et al. [9], and what would be physiologically
achievable as a result of contraction of the plasma volume.
Furthermore, concurrent changes of equal magnitude in
intravascularly distributed endogenous substances with a
relatively constant production, such as albumin and ery-
throcytes, were not seen, which is not in keeping with the
fluid shift hypothesis. In conclusion, we argue that the
majority of the observed fluctuations in the profiles cannot
be explained by physiological or assay variability and
should be considered genuine.
Now that we have demonstrated that the observed
fluctuations in MAb pharmacokinetic profiles are likely to
be genuine, a few considerations are warranted. First, the
occurrence of additional peaks immediately following
administration (\24 h for intravenous and \14 days for
subcutaneous) was usually higher than in the period
thereafter, regardless of the chosen value for normal intra-
subject variability. An explanation for this phenomenon
may be that the sampling frequency is usually decreased
over time, thereby reducing the chance to identify relative
extremes. Additionally, some MAbs had relatively short
profiles, and thus a limited number of data points after
24 h, as was the case for products A and B.
Next, the question arises as to which physiological
mechanism may be responsible for the phenomenon of
fluctuating plasma concentrations. One explanation com-
prises the capture and subsequent release of MAbs by tis-
sues or components, which would presumably be large
quantities of MAbs, given the observed magnitude of the
excursions, with increases of 50% or more (Table 3).
Moreover, a MAb is presumably released quite rapidly, as
the changes over time in certain cases approaches the
infusion rate of intravenous administration (Fig. 1). Earlier,
we demonstrated the endothelium to be a potential candi-
date for dynamically binding biopharmaceuticals [10].
Nonetheless, there may be other locations where MAbs can
be stored temporally. For example, can MAbs simply pool
in the venous compartment or in less perfused organs?
Does an extravascular reservoir exist? Which physiological
or pathophysiological mechanism underlies the release
(‘auto-injection’) of the MAb into the circulation?
Considering daily life, the redistribution of blood flow to
various organs during alimentation (gastrointestinal sys-
tem), resting, and physical exercise (muscles) may either
mask or expose sites for adsorption, absorption, and
elimination, or, in contrast, flush out pooled or adsorbed
MAbs in these organs. Possibly, changes in the local milieu
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(e.g., pH), competition for adsorption sites by other sub-
stances, and modifications to structural components
involved in the binding or transport of MAbs can mediate
the release into the circulation. However, without dedicated
research on the distribution of MAbs over the body, these
options remain speculative at best.
MAbs are designed to specifically bind a particular
target and the resulting complex is internalized and sub-
sequently degraded by either immune cells or the target
cell [3, 5]. Therefore, this elimination process cannot
contribute to increases in the plasma concentration of a
MAb. However, it is conceivable that an abrupt decrease in
the target-mediated elimination route, for example, because
of down-regulation of the target following exposure to an
abundance of circulating MAbs, can acutely elevate plasma
concentrations, provided that there is continuous absorp-
tion of the MAb into the plasma compartment, as with
subcutaneous administration. Other prerequisites for this
possible explanation are a relative high absorption rate and
a significant contribution of the target-mediated pathway to
the total elimination of the MAb, which does not seem to
be the case, based on published values regarding absorption
and elimination rates [2, 11]. By analogy, although varia-
tions in the absorption rate over time after subcutaneous
administration can theoretically change plasma concentra-
tions of MAbs, the absorption of MAbs from a subcuta-
neous depot into the circulation is generally understood to
be slow [4], which is not in line with the observed rapid
and large excursions.
The neonatal Fc receptor (FcRn, or Brambell receptor)
requires special consideration. Binding of a MAb to this
receptor does not result in lysosomal degradation, but
returns the MAb-FcRn complex to the cell membrane
[1–3, 12]. Such recycling of MAbs to the vascular com-
partment may contribute to fluctuations in plasma con-
centrations, as MAbs can be temporarily sequestered from
the circulation [13]. However, research suggests the
transportation of immunoglobulins by FcRn is quite rapid
[14]. Another function of FcRn is transcytosis of
immunoglobulins, including MAbs. According to current
understanding, distribution of MAbs to tissues is slow and
limited [2–5], which suggests this process cannot explain
our observations. Furthermore, albumin is also a substrate
of FcRn [12], and comparable fluctuations in its concen-
tration have not been documented. Nonetheless, involve-
ment of the FcRn cannot be ruled out, although it would be
interesting to know which factors in that case can trigger
abrupt changes in FcRn-mediated transcellular transport
rate of MAbs.
An important question to be answered is what the clin-
ical relevance of fluctuations in plasma concentrations over
time could be. Assuming that plasma concentration is a key
determinant to achieve therapeutic concentrations at the
site of action, measuring and understanding variations in
plasma concentrations over time is probably pivotal.
Therefore, we hope to initiate a broad discussion within the
field on possible explanations for the observed phenomena,
as well as how to increase more fundamental knowledge of
the pharmacokinetics of MAbs.
5 Conclusion
The plasma concentration of MAbs can vary abruptly and
to a great extent, which cannot be explained by normal
physiological or assay variability. Future studies are
required to elucidate this phenomenon and to determine its
relevance for clinical practice.
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